Telomerase activity, Myc and Bcl-2: possible indicators of effective therapy of prostate cancer with 9-nitrocamptothecin.

Abstract

In this report, we demonstrate the down-regulation of telomerase activity and c-Myc and Bcl-2 expression during 9-nitrocamptothecin (9NC)-induced regression of human DU145 prostate tumors grown as xenografts in immunodeficient mice. These changes were not observed in tumors generated by DU145-derived cells resistant to 9NC. We suggest that telomerase activity, c-Myc and Bcl-2 can collectively serve as molecular diagnostic indicators of the effectiveness of 9NC during treatment of human prostate tumors.

• Authors: D Chatterjee, J H Wyche, D P Romero, P Pantazis
• Journal: Anticancer research (Anticancer Res) 2000 Sep-Oct Vol. 20 Issue 5A Pg. 2885-9 ISSN: 0250-7005 [Print] Greece
• PMID: 11062697 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Proto-Oncogene Proteins c-bcl-2
• Proto-Oncogene Proteins c-myc
• Telomerase
• rubitecan
• Camptothecin

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor
• Camptothecin (analogs & derivatives, therapeutic use)
• Humans
• Male
• Mice
• Neoplasm Transplantation
• Prostatic Neoplasms (drug therapy, enzymology, physiopathology)
• Proto-Oncogene Proteins c-bcl-2 (biosynthesis)
• Proto-Oncogene Proteins c-myc (biosynthesis)
• Telomerase (metabolism)